fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Calcitonin (salmon synthetic)

All injection strengths: general benefit

Calcimar · DIN 01926691 · 400 IU/2 mL · injection solution-2mL Pk

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-09-10 — choose a marketed DIN from the same-category list.Discontinued September 10, 2026 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-09-10 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-09-10 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Calcimar · DIN 01926691 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2026-09-10 · brand CALCIMAR · ATC H05BA01 CALCITONIN (SALMON SYNTHETIC) · form Solution · route Subcutaneous, Intramuscular · ingredients CALCITONIN (SALMON SYNTHETIC) 200 UNIT/ML · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Calcimar: Formulary list price $65.44 per unit (the source does not state the unit; exact figure $65.4400). What the ministry pays, not the patient.

Ministry pays: $65.4400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01926691)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 01926691). DIN 01926691: Calcimar Raw flags: dinStatus=E, sec3=Y Item: 682400009; group id 787; item number 1916; lccId None; manufacturer id SAV Source form: Inj Sol-2mL Pk; strength: 400IU/2mL Recorded listing: General benefit; DIN status E, meaning unconfirmed Source prices (unrounded): $65.4400; ministry $65.4400 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926691 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12837
Shortage status: discontinued (August 28, 2026, reported by SANOFI-AVENTIS CANADA INC) · Tier 3; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926691
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 10, 2026 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (68:24 Parathyroid Agents) and how they are covered

Matched class: 68:24 Parathyroid Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 68:24 Parathyroid Agents

TERIPARATIDE

· 4 products · Limited Use, codes 676 (3), Limited Use, codes 635 (1) · strengths: 250mcg/mL · Inj Sol-2.4mL Pref Pen, Inj Sol-3mL Cart Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:24
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS 1. Paget's Disease: Treatment of symptomatic Paget's disease, only in patients who do not respond to alternative treatments or for whom such treatments are not suitable. 2. Hypercalcemia: Early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin may be used in patients with azotemia and those with limited cardiac reserve in whom intravenous fluids may be contraindicated. Due to evidence of an increased risk of malignancies with the long term calcitonin use, the treatment duration should be limited to the shortest period of time possible and using the minimum effective dose. 2 https://pdf.hres.ca/dpd_pm/00057227.PDF PM date: June 3, 2020 Source product: CALCIMAR; DIN 01926691; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Calcimar · DIN 01926691 Shortage status: discontinued (2026-08-28, reported by SANOFI-AVENTIS CANADA INC) · Tier 3; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926691

Check this DIN again